Takeda Pharmaceutical Company Limited (TKDA) — Capital Reinvestment Ratio
Takeda Pharmaceutical Company Limited (TKDA) has a Capital Reinvestment Ratio of 0.60x as of December 2025, meaning it reinvests 1% of its operating cash flow (€373.25 Billion) in capital expenditures (€222.37 Billion). Check tangible equity quality of Takeda Pharmaceutical Company Limited to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Takeda Pharmaceutical Company Limited Capital Reinvestment Ratio (2017–2025)
This chart tracks Takeda Pharmaceutical Company Limited's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see Takeda Pharmaceutical Company Limited cash conversion from operations.
Annual Capital Reinvestment Ratio for Takeda Pharmaceutical Company Limited (2017–2025)
Year-by-year Capital Reinvestment Ratio for Takeda Pharmaceutical Company Limited from 2017 to 2025. See free cash flow generation of Takeda Pharmaceutical Company Limited to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | €1.06 Trillion | €379.62 Billion | ▼ -46.5% |
| 2024 | 0.67x | €716.34 Billion | €480.73 Billion | ▲ +3.5% |
| 2023 | 0.65x | €977.16 Billion | €633.69 Billion | ▲ +490.9% |
| 2022 | 0.11x | €1.12 Trillion | €123.25 Billion | ▼ -0.2% |
| 2021 | 0.11x | €1.01 Trillion | €111.21 Billion | ▼ -42.0% |
| 2020 | 0.19x | €669.75 Billion | €127.08 Billion | ▼ -19.8% |
| 2019 | 0.24x | €328.48 Billion | €77.68 Billion | ▲ +33.4% |
| 2018 | 0.18x | €377.85 Billion | €67.00 Billion | ▼ -24.8% |
| 2017 | 0.24x | €261.36 Billion | €61.66 Billion | — |